Manufacturing

The high cost of exogenous growth factors like BMP-2 remains a major financial barrier to the commercial production of living, engineered bone substitutes. For decades, the reliance on these expensive proteins has restricted high-end tissue engineering to academic research, but the landscape is

Engineering stable microbial cell factories requires genetic tools that function reliably when integrated into the chromosome rather than relying on high-copy plasmids. This foundational principle guided a recent high-impact collaboration between scientific teams in Argentina and Spain, who sought

The movement toward off-the-shelf immunotherapy is solving the scalability issues that have long limited the reach of personalized autologous cellular treatments in oncology clinics. While chimeric antigen receptor (CAR) T-cell therapies have established a foundational success in treating

Disconnected development environments often lead to inconsistent patching across different product variants, creating dangerous gaps in device security. As medical devices evolve into complex, software-defined ecosystems, the traditional boundaries between hardware and digital connectivity have

The Joint Steering Committee oversees a research pipeline that allows for the rapid pivot toward new health threats as they emerge in the Southern Hemisphere landscape. This strategic collaboration between Moderna and CSIRO establishes a robust biosecurity framework intended to fortify Australia’s

With BD products being used in ninety percent of U.S. hospital visits, the company's move to solidify domestic production is a cornerstone of national health security. For decades, the globalized medical supply chain prioritized cost efficiency over redundancy, leaving healthcare providers